Paul Romness, Chairman, CEO, and President of OS Therapies, joins us to discuss the company’s innovative immunotherapy approach for osteosarcoma. He explains how OS Therapies is working to improve outcomes for patients with rare cancers through next-generation treatments.
February 7, 2023
